

Patricia L Winokur

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4706186/publications.pdf>

Version: 2024-02-01

77
papers

3,813
citations

172457
29
h-index

128289
60
g-index

77
all docs

77
docs citations

77
times ranked

4298
citing authors

#	ARTICLE	IF	CITATIONS
1	Population Pharmacokinetic-Pharmacodynamic Model of Oxfendazole in Healthy Adults in a Multiple Ascending Dose and Food Effect Study and Target Attainment Analysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0143221.	3.2	0
2	Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older. <i>Vaccine</i> , 2021, 39, 1339-1348.	3.8	2
3	Human Antibody Responses Following Vaccinia Immunization Using Protein Microarrays and Correlation With Cell-Mediated Immunity and Antibody-Dependent Cellular Cytotoxicity Responses. <i>Journal of Infectious Diseases</i> , 2021, 224, 1372-1382.	4.0	10
4	Population Pharmacokinetic Model of Oxfendazole and Metabolites in Healthy Adults following Single Ascending Doses. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	5
5	Pharmacokinetics, Safety, and Tolerability of Oxfendazole in Healthy Adults in an Open-Label Phase 1 Multiple Ascending Dose and Food Effect Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	17
6	Five Percent Monolaurin Vaginal Gel for the Treatment of Bacterial Vaginosis: A Randomized Placebo-Controlled Trial. <i>Journal of Lower Genital Tract Disease</i> , 2020, 24, 277-283.	1.9	4
7	High dose trivalent influenza vaccine compared to standard dose vaccine in patients with rheumatoid arthritis receiving TNF-alpha inhibitor therapy and healthy controls: Results of the DMID 10-0076 randomized clinical trial. <i>Vaccine</i> , 2020, 38, 3934-3941.	3.8	10
8	Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial. <i>PLoS ONE</i> , 2019, 14, e0222178.	2.5	18
9	Development and validation of a simple, fast, and sensitive LC/MS/MS method for the quantification of oxfendazole in human plasma and its application to clinical pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 171, 111-117.	2.8	14
10	Pharmacokinetics, Safety, and Tolerability of Oxfendazole in Healthy Volunteers: a Randomized, Placebo-Controlled First-in-Human Single-Dose Escalation Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	29
11	A randomized, placebo-controlled phase I trial of live, attenuated herpes zoster vaccine in subjects with end-stage renal disease immunized prior to renal transplantation. <i>Transplant Infectious Disease</i> , 2018, 20, e12874.	1.7	19
12	Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. <i>Vaccine</i> , 2018, 36, 606-614.	3.8	14
13	Safety and immunogenicity of seasonal trivalent inactivated influenza vaccines in pregnant women. <i>Vaccine</i> , 2018, 36, 8054-8061.	3.8	20
14	Quantification of Cefepime, Meropenem, Piperacillin, and Tazobactam in Human Plasma Using a Sensitive and Robust Liquid Chromatography-Tandem Mass Spectrometry Method, Part 1: Assay Development and Validation. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	14
15	Quantification of Cefepime, Meropenem, Piperacillin, and Tazobactam in Human Plasma Using a Sensitive and Robust Liquid Chromatography-Tandem Mass Spectrometry Method, Part 2: Stability Evaluation. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	11
16	Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial. <i>Vaccine</i> , 2017, 35, 1675-1682.	3.8	17
17	Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 1255-1265.	9.1	70
18	Tularemia vaccine: Safety, reactogenicity, skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain "A phase 2 randomized clinical Trial. <i>Vaccine</i> , 2017, 35, 4730-4737.	3.8	30

#	ARTICLE	IF	CITATIONS
19	CD11a and CD49d enhance the detection of antigen-specific T cells following human vaccination. <i>Vaccine</i> , 2017, 35, 4255-4261.	3.8	33
20	Increased Mortality Rates Associated with <i>Staphylococcus aureus</i> and Influenza Co-infection, Maryland and Iowa, USA1. <i>Emerging Infectious Diseases</i> , 2016, 22, 1253-1256.	4.3	29
21	Priming Vaccination With Influenza Virus H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster Vaccination. <i>Journal of Infectious Diseases</i> , 2016, 214, 1020-1029.	4.0	6
22	Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine. <i>Vaccine</i> , 2016, 34, 547-554.	3.8	4
23	Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules. <i>Pediatrics</i> , 2016, 137, e20152603.	2.1	28
24	Rapid, Culture-Free Detection of <i>Staphylococcus aureus</i> Bacteremia. <i>PLoS ONE</i> , 2016, 11, e0157234.	2.5	12
25	Safety and Immunogenicity of Full-Dose Trivalent Inactivated Influenza Vaccine (TIV) Compared With Half-Dose TIV Administered to Children 6 Through 35 Months of Age. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2015, 4, 214-224.	1.3	26
26	Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons ≥18 Years Old. <i>Journal of Infectious Diseases</i> , 2015, 212, 552-561.	4.0	11
27	Association between microbial characteristics and poor outcomes among patients with methicillin-resistant <i>Staphylococcus aureus</i> pneumonia: a retrospective cohort study. <i>Antimicrobial Resistance and Infection Control</i> , 2015, 4, 51.	4.1	5
28	Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine. <i>Journal of Infectious Diseases</i> , 2015, 212, 525-530.	4.0	11
29	Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects. <i>Vaccine</i> , 2015, 33, 5225-5234.	3.8	92
30	Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu102.	0.9	11
31	Immunogenicity of Avian Influenza A/Anhui/01/2005(H5N1) Vaccine With MF59 Adjuvant. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1420.	7.4	45
32	Serological Responses to an Avian Influenza A/H7N9 Vaccine Mixed at the Point-of-Use With MF59 Adjuvant. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1409.	7.4	126
33	Phase II randomized, double-blinded comparison of a single high dose (5 \times 10 ⁸ TCID ₅₀) of modified vaccinia Ankara compared to a standard dose (1 \times 10 ⁸ TCID ₅₀) in healthy vaccinia-naïve individuals. <i>Vaccine</i> , 2014, 32, 2732-2739.	3.8	29
34	Impact of Body Mass Index on Immunogenicity of Pandemic H1N1 Vaccine in Children and Adults. <i>Journal of Infectious Diseases</i> , 2014, 210, 1270-1274.	4.0	43
35	Safety and immunogenicity of IMVAMUNE [®] smallpox vaccine using different strategies for a post event scenario. <i>Vaccine</i> , 2013, 31, 3025-3033.	3.8	57
36	Safety and Immunological Outcomes Following Human Inoculation With Nontypeable <i>Haemophilus influenzae</i> . <i>Journal of Infectious Diseases</i> , 2013, 208, 728-738.	4.0	18

#	ARTICLE	IF	CITATIONS
37	Analysis of Nontypeable Haemophilus influenzae Phase-Variable Genes During Experimental Human Nasopharyngeal Colonization. <i>Journal of Infectious Diseases</i> , 2013, 208, 720-727.	4.0	70
38	Long-Term Risk for Readmission, Methicillin-Resistant Staphylococcus aureus (MRSA) Infection, and Death among MRSA-Colonized Veterans. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1169-1172.	3.2	22
39	Higher Antigen Content Improves the Immune Response to 2009 H1N1 Influenza Vaccine in HIV-Infected Adults: A Randomized Clinical Trial. <i>Journal of Infectious Diseases</i> , 2012, 205, 703-712.	4.0	26
40	Safety and Immune Responses in Children After Concurrent or Sequential 2009 H1N1 and 2009-2010 Seasonal Trivalent Influenza Vaccinations. <i>Journal of Infectious Diseases</i> , 2012, 206, 828-837.	4.0	8
41	Immunogenicity and Safety of Varying Dosages of a Monovalent 2009 H1N1 Influenza Vaccine Given With and Without AS03 Adjuvant System in Healthy Adults and Older Persons. <i>Journal of Infectious Diseases</i> , 2012, 206, 811-820.	4.0	36
42	Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009. <i>Vaccine</i> , 2012, 30, 4240-4248.	3.8	27
43	Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults. <i>Vaccine</i> , 2011, 29, 5666-5674.	3.8	63
44	Active choice but not too active: Public perspectives on biobank consent models. <i>Genetics in Medicine</i> , 2011, 13, 821-831.	2.4	127
45	A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. <i>Vaccine</i> , 2010, 28, 2076-2079.	3.8	99
46	Community-Associated Methicillin-Resistant <i>Staphylococcus aureus</i> , Iowa, USA. <i>Emerging Infectious Diseases</i> , 2009, 15, 1582-1589.	4.3	37
47	BD Phoenix and Vitek 2 Detection of <i>mecA</i> -Mediated Resistance in <i>Staphylococcus aureus</i> with Cefoxitin. <i>Journal of Clinical Microbiology</i> , 2009, 47, 2879-2882.	3.9	25
48	Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. <i>Vaccine</i> , 2009, 27, 5091-5095.	3.8	52
49	Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine. <i>Vaccine</i> , 2008, 26, 4057-4061.	3.8	28
50	Development of a Prediction Rule for Methicillin-Resistant <i>Staphylococcus aureus</i> and Vancomycin-Resistant <i>Enterococcus</i> Carriage in a Veterans Affairs Medical Center Population. <i>Infection Control and Hospital Epidemiology</i> , 2008, 29, 969-971.	1.8	19
51	Predictors of Antimicrobial-Resistant <i>Escherichia coli</i> in the Feces of Vegetarians and Newly Hospitalized Adults in Minnesota and Wisconsin. <i>Journal of Infectious Diseases</i> , 2008, 197, 430-434.	4.0	28
52	Strain-Relatedness of Methicillin-Resistant <i>Staphylococcus aureus</i> Isolates Recovered from Patients with Repeated Infection. <i>Clinical Infectious Diseases</i> , 2008, 46, 1241-1247.	5.8	51
53	Emergence of the USA300 Strain of Methicillin-Resistant <i>Staphylococcus aureus</i> in a Burn-Trauma Unit. <i>Journal of Burn Care and Research</i> , 2008, 29, 790-797.	0.4	15
54	Reducing the Dose of Smallpox Vaccine Reduces Vaccine-Associated Morbidity without Reducing Vaccination Success Rates or Immune Responses. <i>Journal of Infectious Diseases</i> , 2007, 195, 826-832.	4.0	17

#	ARTICLE	IF	CITATIONS
55	Distinct gene expression profiles in peripheral blood mononuclear cells from patients infected with vaccinia virus, yellow fever 17D virus, or upper respiratory infections. <i>Vaccine</i> , 2007, 25, 6458-6473.	3.8	31
56	Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. <i>Vaccine</i> , 2007, 25, 7656-7663.	3.8	151
57	Antimicrobial Drug-Resistant <i>Escherichia coli</i> from Humans and Poultry Products, Minnesota and Wisconsin, 2002-2004. <i>Emerging Infectious Diseases</i> , 2007, 13, 838-846.	4.3	190
58	Association between ceftiofur use and isolation of <i>Escherichia coli</i> with reduced susceptibility to ceftriaxone from fecal samples of dairy cows. <i>American Journal of Veterinary Research</i> , 2006, 67, 1696-1700.	0.6	105
59	Emergence of Two <i>Klebsiella pneumoniae</i> Isolates Harboring Plasmid-Mediated CTX-M-15 β -Lactamase in Taiwan. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 362-363.	3.2	17
60	Surveillance in Taiwan Using Molecular Epidemiology for Extended-Spectrum Beta-Lactamase-Producing <i>Klebsiella pneumoniae</i> . <i>Infection Control and Hospital Epidemiology</i> , 2004, 25, 812-818.	1.8	10
61	Vaccination Success Rate and Reaction Profile With Diluted and Undiluted Smallpox Vaccine. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 1205.	7.4	53
62	Confirmation of extended-spectrum β -lactamase-producing <i>Serratia marcescens</i> : preliminary report from Taiwan. <i>Diagnostic Microbiology and Infectious Disease</i> , 2003, 45, 221-224.	1.8	26
63	Phylogenetic Origin and Virulence Genotype in Relation to Resistance to Fluoroquinolones and/or Extended-Spectrum Cephalosporins and Cephamycins among <i>Escherichia coli</i> isolates from Animals and Humans. <i>Journal of Infectious Diseases</i> , 2003, 188, 759-768.	4.0	227
64	First Description of <i>Klebsiella pneumoniae</i> Harboring CTX-M β -Lactamases (CTX-M-14 and CTX-M-3) in Taiwan. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 1098-1100.	3.2	44
65	Cefepime MIC as a Predictor of the Extended-Spectrum β -Lactamase Type in <i>Klebsiella pneumoniae</i> , Taiwan. <i>Emerging Infectious Diseases</i> , 2002, 8, 522-524.	4.3	36
66	Characterization of extended spectrum β -lactamase-producing <i>Klebsiella pneumoniae</i> from Beijing, China. <i>International Journal of Antimicrobial Agents</i> , 2001, 18, 185-188.	2.5	11
67	Carbapenem-resistant <i>Serratia marcescens</i> isolates producing Bush group 2f β -lactamase (SME-1) in the United States: results from the MYSTIC Programme. <i>Diagnostic Microbiology and Infectious Disease</i> , 2001, 39, 125-127.	1.8	37
68	Variations in the Prevalence of Strains Expressing an Extended-Spectrum β -Lactamase Phenotype and Characterization of Isolates from Europe, the Americas, and the Western Pacific Region. <i>Clinical Infectious Diseases</i> , 2001, 32, S94-S103.	5.8	352
69	Evidence for Transfer of CMY-2 AmpC β -Lactamase Plasmids between <i>Escherichia coli</i> and <i>Salmonella</i> Isolates from Food Animals and Humans. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 2716-2722.	3.2	365
70	Animal and Human Multidrug-Resistant, Cephalosporin-Resistant <i>Salmonella</i> Isolates Expressing a Plasmid-Mediated CMY-2 AmpC β -Lactamase. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 2777-2783.	3.2	265
71	Molecular Characterization of the β -Lactamases from Clinical Isolates of <i>Moraxella</i> (<i>Branhamella</i>) <i>catarrhalis</i> Obtained from 24 U.S. Medical Centers during 1994-1995 and 1997-1998. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 444-446.	3.2	25
72	Russian <i>Klebsiella pneumoniae</i> isolates that express extended-spectrum β -lactamases. <i>Clinical Microbiology and Infection</i> , 2000, 6, 103-108.	6.0	3

#	ARTICLE	IF	CITATIONS
73	Antimicrobial susceptibility of bacteria causing urinary tract infections in Latin American hospitals: results from the SENTRY Antimicrobial Surveillance Program (1997). <i>Clinical Microbiology and Infection</i> , 1999, 5, 478-487.	6.0	20
74	Characteristics of pathogens causing urinary tract infections in hospitals in North America: results from the SENTRY Antimicrobial Surveillance Program, 1997. <i>Diagnostic Microbiology and Infectious Disease</i> , 1999, 35, 55-63.	1.8	120
75	Phenotypic and genotypic characterizations of chinese strains of <i>Escherichia coli</i> producing extended-spectrum β -lactamases. <i>Diagnostic Microbiology and Infectious Disease</i> , 1999, 34, 159-164.	1.8	15
76	Identification of Single Amino Acids in the Human Papillomavirus 11 E2 Protein Critical for the Transactivation or Replication Functions. <i>Virology</i> , 1998, 241, 312-322.	2.4	35
77	The Transactivation and DNA Binding Domains of the BPV-1 E2 Protein Have Different Roles in Cooperative Origin Binding with the E1 Protein. <i>Virology</i> , 1996, 221, 44-53.	2.4	35